As the hub and spoke model is adopted by more stroke centers, questions arise regarding how best to manage patients after an initial telemedicine consultation. It is neither practical nor possible to transfer all patients treated with tPA to Background and Purpose-Telemedicine is increasingly utilized for intravenous tPA (tissue-type plasminogen activator) delivery. The comparative safety of leaving tPA-treated patients at a presenting (spoke) hospital (drip-and-stay) or transferring patients to a central treating (hub) hospital (drip-and-ship) is not established. We sought to compare outcomes between drip-and-ship and drip-and-stay patients treated with tPA via telemedicine. We hypothesized that there would be no differences in short-term outcomes of in-hospital mortality, length of stay, or discharge disposition or in 90-day outcomes between groups. Methods-We retrospectively identified patients treated with tPA at 17 spoke hospitals between September 2015 and December 2016. Demographic, clinical, and outcome data were obtained from a prospective telemedicine registry. We used negative binomial, multinomial, and logistic regression analyses to evaluate length of stay, discharge disposition, and inpatient mortality, respectively. We compared the proportion of patients with 90-day modified Rankin Scale score <2 by group. Results-Among 430 tPA-treated patients, 232 (53.9%) were transferred to the hub after treatment. The median arrival National Institutes of Health Stroke Scale score was higher for drip-and-ship (10; interquartile range, 5-18) compared with drip-and-stay patients (6; interquartile range, 4-10; P<0.001). Unadjusted length of stay was longer in drip-and-stay patients (incidence rate ratio, 0.82; 95% CI, 0.71-0.95). There were no significant differences in adjusted length of stay, hospital mortality, or discharge disposition. Among the 64% of patients with complete 90-day modified Rankin Scale score, the proportion with good outcomes (modified Rankin Scale score <2) did not differ between groups. Conclusions-We found no differences in measured outcomes between drip-and-ship and drip-and-stay patients treated in our network, although our study may be underpowered to detect small differences. (Stroke. 2019;50:895-900.
T he use of intravenous tPA (tissue-type plasminogen activator) for acute stroke has been approved by the US Food and Drug Administration for over 20 years, yet the rate of tPA treatment remains low. [1] [2] [3] [4] There is wide regional variation in tPA treatment, and some of the variation has been attributed to treatment access. 2 Many stroke programs are striving to improve stroke outcomes by using telemedicine to expand access to stroke neurologists with a goal of increasing the proportion of eligible patients treated with tPA. One study revealed an increase in tPA treatment from 2.8% to 6.8% of eligible patients after telemedicine implementation, whereas another demonstrated improved 60-minute access to acute stroke care for 2 million Texans with the use of telemedicine. 5, 6 The hub and spoke model constitutes a system in which patients presenting to outlying spoke hospitals are treated via telemedicine by stroke specialists at a central, often larger, hub hospital.
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April 2019 the hub hospitals. Many patients with stroke who receive tPA via telemedicine remain at the spoke (drip-and-stay), whereas other, often more complex cases are transferred to the hub (drip-and-ship). Spoke hospitals often lack 24-hour neurology or stroke coverage and do not typically have comparable volumes of patients with stroke. 3 The comparative effectiveness of retaining telemedicine-consulted, tPA-treated patients with stroke at spoke hospitals versus transferring patients to hub hospitals is not established.
A number of studies have assessed thrombolysis metrics and clinical outcomes among patients with ischemic stroke treated with tPA via telemedicine. [8] [9] [10] [11] [12] The majority of these studies compared telemedicine-treated tPA patients to patients treated at regional stroke centers. Audebert et al 11 compared processes of tPA management and tPA complications between patients treated with tPA via telemedicine at community hospitals and patients treated at a regional stroke center. They reported longer door-to-needle (DTN) times in community hospitals but no significant differences in symptomatic intracerebral hemorrhage (sICH) or early mortality. 11 Schwab et al 12 reported similar 90-day mortality and functional outcomes among patients treated via telemedicine and patients treated at stroke centers. Pervez et al 10 compared drip-and-ship patients treated in a hub and spoke network to hub-treated patients and found similar mortality rates, sICH, discharge disposition, and functional outcomes in these 2 groups.
Fewer studies compare outcomes between drip-and-ship and drip-and-stay patients. 13, 14 One prior study demonstrated similar in-hospital mortality comparing these groups. 13 To our knowledge, only 1 group has published a more extensive comparison of outcomes between drip-and-stay and drip-and-ship tPA-treated patients.
14 This study showed unfavorable results as relates to length of stay (LOS), in-hospital mortality, and discharge disposition among drip-and-stay patients. The findings have not been replicated in other systems or with a larger patient population. More studies comparing outcomes between drip-and-stay and drip-and-ship patients are needed. We sought to compare in-hospital mortality, LOS, discharge disposition, and functional outcome based on 90-day modified Rankin Scale (mRS) scores between drip-and-stay and drip-and-ship patients treated with tPA in our large telemedicine network.
Methods

Study Design
The study was conducted with Institutional Review Board approval using data from the Lone Star Stroke Consortium Telemedicine Stroke Registry. Lone Star Stroke Consortium Telemedicine Stroke Registry is a statewide initiative organized to understand practice patterns of acute stroke management via telemedicine across the state of Texas. 15 The registry includes all video consults for presumed patients with stroke within our teleneurology network. The registry includes metrics related to tPA treatment, details regarding individual patient demographic data and medical history, and outcomes, including tPA complications, discharge disposition, mortality, and 90-day mRS score. Ninety-day outcomes are obtained by phone call. Data are abstracted from medical records by trained abstractors, and database quality is managed by a central coordinating center at the McGovern Medical School at the University of Texas Health Sciences Center at Houston (UTHealth). Because the data analyzed for this study were made available by the Lone Star Stroke Consortium, requests to access the dataset from qualified researchers trained in human subjects confidentiality protocols must be sent to T. Patients were included in the current retrospective study if they received IV tPA via telemedicine for an acute ischemic stroke between September 2015 and December 2016 at 1 of the 17 spoke hospitals in the UTHealth Teleneurology Network. Patients who transferred from the spoke hospital to a nonhub hospital within the system were excluded. Demographic characteristics, including age, sex, race, and insurance status, were assessed. Race/ethnicity categories were defined as follows: non-Hispanic white/white, black, Hispanic, and Asian. Insurance status was categorized as insured or uninsured. Comorbid risk factors, including hypertension, hyperlipidemia, diabetes mellitus, prior stroke, coronary artery disease, atrial fibrillation, chronic obstructive pulmonary disease, end-stage renal disease, peripheral vascular disease, active tobacco use, and congestive heart failure, were obtained from the registry. Arrival National Institutes of Health Stroke Scale (NIHSS) score was categorized according to severity as mild (0-4), moderate (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , and moderately severe to severe (≥16). DTN times, stroke presentation location (inpatient versus emergency department), and data pertaining to endovascular therapy (EVT) assessment and treatment were assessed. Primary outcomes of in-hospital mortality, LOS, and discharge disposition; good functional outcome according to 90-day mRS of 0 or 1; and rates of sICH were obtained from the registry.
Statistical Analysis
STATA, version 14, was used for all analyses. Baseline patient and hospital characteristics were compared by group using t tests and Wilcoxon rank-sum tests for continuous variables and χ 2 analyses for categorical variables. Fischer exact test was used for comparison of sICH with a P of 0.816. The LOS data were overdispersed (variance greater than mean); therefore, a negative binomial regression analysis was chosen for analysis (likelihood ratio test; P<0.001). The regression was run on the demographic and medical covariates to determine their individual relationships with LOS with drip-and-ship as reference. For this and each of the following multivariable analyses, covariates with P<0.1 and variables previously shown to be associated with the outcomes of interest in patients with stroke were included in the initial models. All patients who underwent EVT were transferred to the hub for treatment, and as such, we could not adjust for this in the multivariable models. These patients were excluded from the regression analyses. The strongest predictive models were selected using Akaike and Bayesian information criteria and likelihood ratio testing. Hospital characteristics, including distance from the hub (categorical variable, ≥60 versus <60 miles) and relationship to hub (Memorial Hermann-affiliated hospital versus other), were included in all models. The negative binomial regression model comparisons are reported as incidence rate ratios, with drip-and-ship as reference. Multinomial logistic regression was used for analysis of discharge disposition. Disposition categories include home (base variable), inpatient rehabilitation, skilled nursing facility/long-term acute-care facility/nursing home, and death/hospice. The final multinomial regression was selected as above with comparisons reported as relative risk ratios. In-hospital mortality was analyzed using logistic regression, and criteria above was used for variable inclusion in the initial model with comparisons reported as odds ratios. Postestimation assessment of model fit was conducted by cross tabulation and visual inspection of graphic depiction of observed versus predicted values and residual analyses. For the multinomial and logistic regression models, Hosmer-Lemeshow goodness-of-fit tests were performed. Because DTN time was not applicable for patients who had symptom onset during hospital admission (inpatient strokes), we performed sensitivity analyses that included DTN time for all outcomes. Ninetyday mRS scores were missing for 34.4% of patients. We provide descriptive statistics for this outcome.
Results
Among 455 patients meeting inclusion criteria, 25 patients were excluded because they were transferred to a nonhub hospital. Among excluded patients, median NIHSS was 7 (IQR, 3-15), mean age was 67.5 years (SD, 12.9), and 60% were men. The median distance in miles from the hub was significantly greater for these patients (88 miles; IQR, 73-95) compared with the included patients (73 miles; IQR, 32-95). Of the remaining 430 patients, 232 (54%) were transferred to the hub hospital (drip-and-ship) and 198 remained at the community hospital (drip-and-stay). Among drip-and-ship patients, 32 (13.8%) were transferred to the hub for EVT.
Patient demographic data did not differ significantly between drip-and-stay and drip-and-ship groups (Table 1) . Regarding clinical data, drip-and-stay patients were more likely to have a preadmission diagnosis of chronic obstructive pulmonary disease. The median presenting NIHSS was significantly lower (P<0.05) among drip-and-stay (6; -IQR, 4-10) compared with drip-and-ship patients (10; IQR, 5-18). The proportion of inpatient strokes did not differ between groups. Among patients presenting to the emergency department for initial assessment, median DTN time was significantly longer in drip-and-stay (64 minutes; IQR, 51.5-78.5) compared with drip-and-ship patients (58 minutes; IQR, 46-81; P=0.03). This difference was driven by the shorter DTN time (47.5 minutes; IQR, 37.5-58.5) among the 32 patients who were all transferred to the hub for endovascular treatment. Rates of sICH were low and did not differ between groups in the univariate analysis (drip-and-ship, 4.74%, versus drip-and-stay, 4.04%; P=0.82) or after adjustment for arrival NIHSS (odds ratio [drip-andstay versus drip-and-ship], 1.29; 95% CI, 0.48-3.46).
Summary statistics for hospital characteristics are also shown in Table 1 . The median number of hospital beds did not differ between groups (P=0.08). Among drip-and-ship patients, the median distance was significantly greater (88 miles; IQR, 73-95) compared with patients who remained at spoke hospitals (32 miles; IQR, 12-73; P<0.0001). Patients were more likely to be retained at hub-affiliated spoke hospitals (P<0.001). There was no significant difference in the proportion of drip-and-ship compared with drip-and-stay patients who received initial treatment at a PSC.
The median LOS was significantly shorter among dripand-stay patients (3; IQR, 2-6) versus drip-and-ship patients (4; IQR, 2-8; P<0.001) when EVT and non-EVT patients were considered. The results of the regression analyses, which included non-EVT patients (n=398), are shown in Table 2 . Drip-and-stay patients had an estimated 0.91-day shorter (99% CI, 0.29; 1.53 days) LOS in the univariate negative binomial regression analysis (incidence rate ratio, 0.82; 95% CI, 0.71-0.95). In the final regression model, which included age, sex, race/ethnicity, insurance status, prior diabetes mellitus, prior congestive heart failure, stroke severity (NIH category), distance from hub (<60 versus ≥60 miles), and relationship to hub (hub-affiliated hospital versus other), LOS was not significantly different between groups (incidence rate ratio, 0.87; 95% CI, 0.73-1.03).
Overall in-hospital mortality was low (4.65%) as compared with prior estimates and did not differ between drip-and-stay (4.04%) and drip-and-ship (5.17%) patients in the univariate analysis. 16 In-hospital mortality did not significantly differ in the univariate or the multivariable logistic regression models ( Table 2 ). The multivariable model included age, stroke severity (NIHSS category), inpatient versus emergency department presentation, history of atrial fibrillation, distance from hub (<60 versus ≥60 miles), and relationship to hub as covariates (odds ratio, 1.81; 95% CI, 0.49-6.74).
Regarding discharge disposition, there appeared to be a higher proportion of drip-and-stay versus drip-and-ship patients discharged home (62.4% versus 55.5%) and a higher proportion of drip-and-ship versus drip-and-stay patients discharged to inpatient rehabilitation (23.8% versus 16.7%) when all patients were considered. However, among non-EVT patients, the proportions were more similar between groups (Table 2) . After adjustment for stroke severity, age, insurance status, diabetes mellitus, hypertension, atrial fibrillation, distance from hub (<60 versus ≥60 miles), and relationship to hub (hub-affiliated hospital versus other), there was no difference in discharge disposition between groups (Table 2 ). In sensitivity analyses that included DTN times, short-term outcomes of LOS, in-hospital mortality, and discharge disposition did not significantly differ between drip-and-stay and drip-and-ship groups.
Finally, regarding 90-day mRS scores, interpretation of data is limited by the amount of incomplete data. Data were complete for 74.0% of non-EVT patients transferred to the hub but for only 54.0% of patients who remained at the spoke (P<0.001). Patients with missing data were more likely to be uninsured than insured (adjusted odds ratio, 2.37; 95% CI, 1.22-4.61). Arrival NIHSS and discharge disposition (excluding death) were not associated with likelihood of missing data. The median mRS for drip-and-stay patients was 2 (IQR, 1-4), and the median mRS for non-EVT drip-and-ship patients was 2.5 (IQR, 1-4). Among non-EVT drip-and-ship patients, 32.4% achieved a 90-day mRS score of 0 or 1 compared with 40.2% of drip-and-stay patients (P=0.20).
Discussion
We found that among tPA-treated patients with ischemic stroke in the UTHealth Teleneurology Network, patients with more severe strokes were more likely to be transferred to the hub for
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April 2019 CAD indicates coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DTN, door to needle; ED, emergency department; ESRD, end-stage renal disease; EVT, endovascular therapy; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; PSC, primary stroke center; PVD, peripheral vascular disease; and sICH, symptomatic intracerebral hemorrhage.
treatment as compared with those with milder strokes. Despite differences in initial stroke severity, drip-and-ship and drip-andstay patients did not differ in terms of in-hospital mortality, LOS, or discharge disposition in adjusted analyses. This is not consistent with the findings of a prior study conducted at a tertiary medical center that uses a hub and spoke model for telemedicine treatment. In this prior study, which compared outcomes between 73 drip-and-ship and 134 drip-and-stay patients treated at 5 spoke hospitals in the University of Pittsburg Medical Center system, drip-and-stay patients were older and had lower NIHSS.
14 Despite adjustment for confounding variables, the authors found that drip-and-stay patients were more likely to have LOS >6 days and higher in-hospital mortality. Although this study reflected experiences from a single network, the findings raised concerns about the safety of the drip-and-stay model. A major difference between our current study and the study by the University of Pittsburg Medical Center is the proportion of spoke hospitals with PSC certification. Whereas 29.1% of drip-and-stay patients in the study by the University of Pittsburg Medical Center remained at spoke hospitals with PSC certification, 92.9% of our drip-and-stay patients remained at PSCs. Patients who remain at PSCs may have improved outcomes after tPA treatment via telemedicine because of access to inpatient neurologists, adherence to standard protocols, or treatment in specialized stroke units. 17 Other factors that may explain the differences between these 2 studies include temporal changes and declines in stroke mortality and patient selection variables that were not ascertained in either study. 18 Previous studies have shown that patients who receive tPA via telemedicine and remain at spoke hospitals have similar short-term outcomes to patients who are present initially to a regional or comprehensive stroke center for treatment. [10] [11] [12] In this study, we showed similar short-term outcomes for patients remaining at spoke hospitals after tPA treatment, as compared with tPA-treated patients who were transferred to the hub hospital. Notably, we excluded the drip-and-ship patients who were transferred to the hub for EVT from these analyses, as the EVT indication required transfer for treatment. We also showed no significant difference in the long-term outcome of mRS, with 32% of drip-and-ship patients achieving good functional compared with 40.2% of drip-and-stay patients. The proportions of patients with good outcomes in the dripand-stay and the drip-and-ship groups in this study are similar to those reported in prior studies of telemedicine-treated patients; however, inferences that can be drawn are limited by the proportion of patients with missing data and characteristics of these patients. 10, 12 Ninety-day mRS data were missing for 36% of patients and were more likely to be missing from uninsured and drip-and-stay patients. There are a number of possible reasons for the differences in the degree of missing data between groups. Lack of insurance may reflect lower socioeconomic status and telephone access. Limited access to follow-up care may also be influenced by insurance status and may vary between patients discharged from hub and spoke hospitals. Finally, documentation of contact information and emergency numbers may vary by institution.
Together with previous studies, our findings support the idea that patients with stroke who remain in hospitals providing specialized stroke care after telemedicine-guided tPA treatment have similar short-term outcomes compared with patients treated in regional or comprehensive stroke centers. The findings also support the regionalization of care concept that allows selection of patients for transfer to advanced centers based on the need for higher level of care. Other strengths of this study include the completeness of data for short-term outcomes and the number of spoke sites included. There were significant hospital-level differences between drip-and-ship and drip-and-stay patients. Patients were more likely to be transferred from hospitals that were further from the hub and from hospitals that were not a part of the same hospital system as the hub (Memorial Hermann). Although we controlled for distance from the hub and Memorial Hermann Drip-and-ship is the reference for all analyses. Patients transferred from EVT (n=32) were excluded from analyses. EVT indicates endovascular therapy; IPR, inpatient rehabilitation; IQR, interquartile range; IRR, incidence rate ratio; LOS, length of stay; LTAC, long-term acute-care facility; NH, nursing home; NIH, National Institutes of Health; OR, odds ratio; RRR, relative risk ratio; and SNF, skilled nursing facility.
*IRR reported for LOS, by negative binomial regression with adjustment for age, sex, stroke severity (NIH category), race, insurance status, distance from hub (<60 vs ≥60 miles), and relationship to hub (Memorial Hermann system hospital vs other).
†OR reported for hospital mortality by multivariable logistic regression with adjustment for age, history of atrial fibrillation, stroke severity (NIH category), and inpatient stroke (vs emergency department presentation), distance from hub, and relationship to hub (Memorial Hermann system hospital vs other).
‡RRR reported for discharge disposition by multinomial logistic regression with adjustment for age, insurance status, stroke severity, medical history of diabetes mellitus, hypertension, and atrial fibrillation, distance from hub, and relationship to hub (Memorial Hermann system hospital vs other).
affiliation in all analyses, ≈40% of the sample represents patients from Memorial Hermann spokes. There remains a possibility that resources, quality metrics, or system-level practices within the Memorial Hermann system influence outcomes in these patients, and we could not fully control for these variables. Notably, other large telemedicine networks will also have significant heterogeneity among sites. It is important for such networks to evaluate patient-level outcomes, despite the expected heterogeneity.
DTN times were shorter for drip-and-ship compared with drip-and-stay patients. This was driven by shorter DTN times for patients who were transferred to the hub for endovascular treatment. These shorter times may be related to increased urgency for transfer initiation and increased attention to patients who may require endovascular treatment. As stated, all patients who were eligible for EVT were transferred to the hub for treatment, and we excluded these patients from the outcome analyses.
Although data are collected prospectively in a registry, this study was retrospective, and as such, there were limitations in the number of variables that were available for comparison. Because the study is observational, we could not control for other potential known or unknown confounders. For example, inpatient mortality can be affected by patient preferences around goals of care and hospital resources for facilitating transitions to hospice, and we could not adjust for this. Because we excluded patients who were transferred to nonhub hospitals after tPA treatment, a possibility of selection bias exists; however, excluded patients represent <6% of the total eligible sample. We cannot exclude the possibility that this study was not adequately powered to detect differences in the outcomes of interest, and larger studies are needed to confirm our findings. Finally, we could not fully evaluate differences in longer term outcomes, including 90-day mRS, because these data were incomplete.
Conclusions
In conclusion, we found that EVT-ineligible patients who received tPA via telemedicine in our large network fare the same in terms of in-hospital mortality, LOS, and discharge disposition whether they remained at spoke hospitals or were selected to transfer to the hub hospital. Notably, patients selected for transfer had higher stroke severity, and spoke-retained patients remained at PSCs and hub-affiliated hospitals for post-tPA care. Further multicenter prospective studies are needed to determine which factors should be used to select patients who can safely remain at spoke hospitals.
